BIODESIX BDSX 深 沪
已收盘 12-05 16:00:00 美东时间
7.675
-0.865
-10.13%
华盛通- 最 高8.69
- 今 开8.36
- 成交量 9.77万股
- 最 低 7.62
- 昨 收 8.54
- 总市值 6106.00万
- 52周最高 32.20
- 市盈率 静 --
- 换手率 1.23%
- 52周最低 3.436
- 委 比 9.09%
- 总股本 795.57万
- 历史最高 639.80
- 量 比 2.46
- 振 幅 12.53%
- 历史最低 3.436
- 每 手 1
- 风险率 7.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biodesix To Present Data On Development Of New Ultra-Sensitive ESR1 Test For Initial Detection And Monitoring Of Mutations In HR+/HER2- Advanced Breast Cancers At SABCS
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings.The
12-03 21:28
Biodesix Q3 EPS $(1.16) Beats $(1.45) Estimate, Sales $21.768M Beat $20.974M Estimate
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1.45) by 20 percent. This is a 17.14 percent increase over losses of $(1.40) per share from the same
11-04 05:42
Biodesix Raises FY2025 Sales Guidance from $80.000M-$85.000M to $84.000M-$86.000M vs $83.236M Est
Biodesix (NASDAQ:BDSX) raises FY2025 sales outlook from $80.000 million-$85.000 million to $84.000 million-$86.000 million vs $83.236 million estimate.
11-04 05:04
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
What's Next: Biodesix's Earnings Preview
Biodesix (NASDAQ:BDSX) will release its quarterly earnings report on Monday, 20...
11-01 05:01
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting
Biodesix will present at the 2025 AMP Annual Meeting in Boston, showcasing its R&D roadmap, strategic partnerships, and diagnostic innovations. Key partner updates will be featured in a workshop led by Dr. Gary Pestano, highlighting advancements in molecular testing for faster results, high-throughput, and efficient sample use. Biodesix will also present a poster on circulating tumor cell enrichment at the event.
10-30 10:17
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays
<p>Biodesix announced an expanded partnership with Bio-Rad to develop and validate in vitro diagnostic assays using ddPCR technology for detecting genomic markers in oncology, starting with the ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer. The assay will enable sensitive detection of ESR1 mutations in ctDNA, aiding the development of targeted therapies and monitoring cancer treatment. Biodesix will manufacture and distribute sp...
10-22 10:17
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
Biodesix will present preliminary data from the first 1,000 patients enrolled in the CLARIFY study at the 2025 CHEST Annual Meeting. The study evaluates the performance of Nodify Lung tests in real-world clinical settings, aiming to improve lung nodule management. Additional presentations will highlight the impact of these tests on healthcare resource utilization and patient outcomes. Biodesix leaders will also discuss future biomarker developmen...
10-15 10:09
Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit
Biodesix, a diagnostics solutions company, partners with three Colorado-based lung health organizations to host three events in October for healthcare professionals and patients. The events include a lung nodule education seminar by APAPP, a Lung Cancer Centers of Excellence Summit organized by the Go2 Association, and the American Lung Association's "Run the Rocks" fundraiser. These initiatives aim to promote lung health awareness and education,...
10-06 14:13
Biodesix Regains Nasdaq Compliance with Bid Price
The latest update is out from Biodesix ( ($BDSX) ). On September 26, 2025, Biod...
10-02 04:35
